Literature DB >> 1714929

A potential role for CD1a molecules on human epidermal Langerhans cells in allogeneic T-cell activation.

C Moulon1, J Péguet-Navarro, D Schmitt.   

Abstract

The structural similarities of CD1a molecules to major histocompatibility complex (MHC) class I antigens, as well as their expression on epidermal antigen-presenting cells suggest that CD1a molecules might be involved in the cutaneous immune response. In the present study, we investigated the effect of different anti-CD1a monoclonal antibodies (BL6, DMC1, and Na1/34) on T cell proliferation induced by allogeneic epidermal cells in vitro. A significant inhibition of the mixed skin cell-lymphocyte reaction was obtained with BL6 and DMC1 monoclonal antibodies (MoAb), which recognize the same epitope on CD1a molecule. The observed inhibition could not be related to a steric hindrance of MHC class II molecules, because Na1/34 MoAb, which reacts with another epitope on CD1a molecule, had no significant effect. BL6 and DMC1 MoAb interfered with an early event of T-cell activation, as shown by a time-course study. In the presence of these MoAb, the addition of exogenous interleukin 2 did not restore T-cell proliferation. Furthermore, the inhibitory effect of anti-CD1a MoAb was not mediated by a suppressor factor released by Langerhans cells (LC). These present data suggest that CD1a molecule may have an important function in self peptide presentation by human Langerhans cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714929     DOI: 10.1111/1523-1747.ep12481556

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  2 in total

1.  Functional defect in cells involved in Langerhans cell histiocytosis.

Authors:  R C Yu; M Alaibac; A C Chu
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

2.  Immunohistochemical localization of CD1a-positive putative dendritic cells in human breast tumours.

Authors:  E E Hillenbrand; A M Neville; B J Coventry
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.